{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:27:33Z","timestamp":1776882453408,"version":"3.51.2"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"abstract":"<jats:p>Kinase inhibitors that enter clinical use as treatments for cancer may have off-target effects, making them efficacious in the treatment of autoimmune diseases. Case reports are presented on the potential of erlotinib and gefitinib for treating psoriasis, inflammatory bowel disease, rheumatoid arthritis, and other nonautoimmune inflammatory disorders.<\/jats:p>","DOI":"10.1634\/theoncologist.2012-0219","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T12:42:39Z","timestamp":1359204159000},"page":"e3-e5","source":"Crossref","is-referenced-by-count":11,"title":["Erlotinib and Gefitinib, Epidermal Growth Factor Receptor Kinase Inhibitors, May Treat Non-Cancer-Related Tumor Necrosis Factor-\u03b1 Mediated Inflammatory Diseases"],"prefix":"10.1093","volume":"18","author":[{"given":"Marvin B.","family":"Brooks","sequence":"first","affiliation":[{"name":"Eisenhower Medical Center, Rancho Mirage, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,1,16]]},"reference":[{"key":"2021122308260527800_B1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3410\/M4-5","article-title":"Kinase inhibitors in the treatment of immune-mediated disease","volume":"4","author":"Kontzias","year":"2012","journal-title":"F1000 Med Reports"},{"key":"2021122308260527800_B2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1474651412442694","article-title":"Erlotinib appears to produce prolonged remission of insulin-requiring type 2 diabetes associated with metabolic syndrome and chronic kidney disease","volume":"12","author":"Brooks","year":"2012","journal-title":"Brit J Diab Vasc Dis"},{"key":"2021122308260527800_B3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TN. F-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"2021122308260527800_B4","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/sj.bjc.6602548","article-title":"Selective inhibition of TNF-a induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib","volume":"92","author":"Ueno","year":"2005","journal-title":"B J Cancer"},{"key":"2021122308260527800_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1740-2557-2-1","article-title":"Immunogenics of Hashimoto's thyroiditis","volume":"2","author":"Chistiakov","year":"2005","journal-title":"Jour Autoimmune Dis"},{"key":"2021122308260527800_B6","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Schon","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122308260527800_B7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","article-title":"Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management","volume":"12","author":"Lynch","year":"2007","journal-title":"The Oncologist"},{"key":"2021122308260527800_B8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000232307","article-title":"Management of severe psoriasis with TNF-a antagonists adalimumab, etanercept and infliximab","volume":"38","author":"Mossner","year":"2009","journal-title":"Curr Probl Dermatol"},{"key":"2021122308260527800_B9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0960-894X(00)00718-6","article-title":"Structure-activity relationships of quinazoline derivatives: Dual-acting compounds with inhibitory activities toward both TNF-a production and T cell proliferation","volume":"11","author":"Tobe","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"2021122308260527800_B10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.taap.2010.12.011","article-title":"Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf\/ERK cascade and Akt signaling pathway","volume":"251","author":"Luo","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"2021122308260527800_B11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1172\/JCI29069","article-title":"Inflammation and insulin resistance","volume":"116","author":"Shoelson","year":"2006","journal-title":"J Clin Invest"},{"key":"2021122308260527800_B12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1385\/ENDO:23:2-3:177","article-title":"The role of TNF-alpha in insulin resistance","volume":"23","author":"Borst","year":"2004","journal-title":"Endocrine"},{"key":"2021122308260527800_B13","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gut.2004.047092","article-title":"Increased gut permeability in Crohn's disease: Is TNF-a the link?","volume":"53","author":"Gibson","year":"2004","journal-title":"Gut"},{"key":"2021122308260527800_B14","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1101\/gad.1964410","article-title":"Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses","volume":"24","author":"Tigno-Aranjuez","year":"2010","journal-title":"Genes Dev"},{"key":"2021122308260527800_B15","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.3748\/wjg.v17.i44.4858","article-title":"Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model","volume":"17","author":"Pagan","year":"2011","journal-title":"World J Gastroenterol"},{"key":"2021122308260527800_B16","first-page":"2727","article-title":"Colorectal cancer and inflammatory bowel disease: Epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies","volume":"29","author":"Triantafillidis","year":"2009","journal-title":"Anticancer Res"},{"issue":"24","key":"2021122308260527800_B17","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1158\/0008-5472.CAN-06-2540","article-title":"Tumor necrosis factor-\u03b1 is a potent endogenous mutagen that promotes cellular transformation","volume":"66","author":"Yan","year":"2006","journal-title":"Cancer Res"},{"issue":"suppl 27","key":"2021122308260527800_B18","first-page":"S1","article-title":"The IL-1 family and inflammatory disease","volume":"20","author":"Dinarello","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"2021122308260527800_B19","first-page":"10","article-title":"Interleukin1 or tumor necrosis factor-alpha: Which is the real target in rheumatoid arthritis?","volume":"65","author":"Dayer","year":"2002","journal-title":"J Rheumatol Suppl"},{"key":"2021122308260527800_B20","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: Current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"issue":"5 suppl 27","key":"2021122308260527800_B21","first-page":"S32","article-title":"Anakinra as a new therapeutic option in rheumatoid arthritis: Clinical results and perspectives","volume":"20","author":"Bresnihan","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"2021122308260527800_B22","first-page":"CD007848","article-title":"Biologics for rheumatic arthritis: An overview of Cochrane reviews","volume":"7","author":"Singh","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 28","key":"2021122308260527800_B23","first-page":"S21","article-title":"Is there a rational for combined TNF and IL-1 blocking in arthritis?","volume":"20","author":"Berg","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl 65","key":"2021122308260527800_B24","first-page":"33","article-title":"What are the risks of biologic therapy in rheumatoid arthritis? An update on safety","volume":"29","author":"Weisman","year":"2002","journal-title":"J Rheumatol"},{"key":"2021122308260527800_B25","doi-asserted-by":"crossref","first-page":"e1000591","DOI":"10.1371\/journal.pcbi.1000591","article-title":"Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data","volume":"5","author":"Mitsos","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"2021122308260527800_B26","first-page":"237","article-title":"The role of cytokines in osteoarthritis pathophysiology","volume":"39","author":"Fernandes","year":"2002","journal-title":"Biorheology"},{"key":"2021122308260527800_B27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/11599350-000000000-00000","article-title":"Role of interleukin-1inhibitors in osteoarthritis: An evidence-based review","volume":"29","author":"Jotanovic","year":"2012","journal-title":"Drugs Aging"},{"key":"2021122308260527800_B28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrrheum.2010.196","article-title":"Role of proinflammatory cytokines in the pathophysiology of osteoarthritis","volume":"7","author":"Kapoor","year":"2011","journal-title":"N R Rheum"},{"key":"2021122308260527800_B29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/ard.2011.149849","article-title":"Tumor necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: A double blind, randomized trial on structure modification","volume":"71","author":"Verbruggen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021122308260527800_B30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-009-0872-0","article-title":"Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections","volume":"29","author":"Fioravanti","year":"2009","journal-title":"Rheumatol Int"},{"key":"2021122308260527800_B31","first-page":"111","article-title":"Analgesic effect of gefitinib in the treatment of non-small cell lung cancer","volume":"4","author":"Moryl","year":"2006","journal-title":"J Support Oncol"},{"key":"2021122308260527800_B32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1684\/ejd.2010.0882","article-title":"Improvement of psoriasis in a lung cancer patient treated with erlotinib","volume":"20","author":"Giroux Leprieur","year":"2010","journal-title":"Eur J Dermatol"},{"key":"2021122308260527800_B33","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2337\/dc06-0558","article-title":"Improvement of type 2 diabetes in a lung cancer patient treated with erlotinib","volume":"29","author":"Costa","year":"2006","journal-title":"Diabetes Care"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2012-0219","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0219","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/1\/e3\/41856037\/oncolo_18_1_e3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/1\/e3\/41856037\/oncolo_18_1_e3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:49:18Z","timestamp":1640299758000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/1\/e3\/6410182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,16]]},"published-print":{"date-parts":[[2013,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0219","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,1,1]]},"published":{"date-parts":[[2013,1,1]]}}}